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Special Communications
Periodic Treatment Regimens With 
Inhaled Steroids in Asthma or Chronic 
Obstructive Pulmonary Disease
Is It Possible?
Constant P. van Schayck, PhD; Paul J. J, A, van den Broek, MD; Joost J. den Otter, MD; 
Cees L. A. van Herwaarden, MD, PhD; Johan Molema, MD, PhD; Chris van Weei, MD, PhD
Objective.—To determine whether inhaled corticosteroids can be discontinued 
in the stable phase of asthma or chronic obstructive pulmonary disease (COPD) 
or if this therapy should be continued.
Design.— Nonrandomized open uncontrolled 5-year trial.
Setting.— Prospective study in general practice.
Patients.—Forty-eight patients with steroid-dependent asthma or COPD who 
had shown a decline in forced expiratory volume in 1 second (FEV^ of at least 80 
mL per year and at least one exacerbation per year during the first 2 years of bron- 
chodilator treatment. Subjects were treated additionally with inhaled steroids for 
another 2 years and were finally given the option to stop using steroids. Sixteen 
patients were willing to stop using beclomethasone and were studied for another 
year. No recruitment bias took place in this consecutive sample in the fifth year of 
follow-up. Two of 16 patients developed carcinomas and dropped out.
Interventions.—Two years of bronchodilator treatment alone (400 iulg of salbu- 
tamol or 40 jxg of ipratropium bromide four times daily), followed by 2 years of ad­
ditional inhaled corticosteroid treatment (400 ¡lq of beclomethasone two times 
daily), and finally 1 year of bronchodilator treatment alone.
Main Outcome Measures.—Decline in lung function (FEV^, change in bron­
chial hyperresponsiveness, indicated by a provocative concentration of histamine 
causing a 20% fall in FEV1 (PC2o), morning peak expiratory flow rate (PEFR), di­
urnal PEFR, week-to-week variation of PEFR, bronchial symptoms, and exacer­
bations.
Results.—The course of FEVi during the year in which beclomethasone was 
discontinued was not significantly different when compared with the 2-year period 
of beclomethasone treatment. Neither did the course of PC20j morning PEFR, di­
urnal PEFR, symptom score, and exacerbation rate change. Only the week-to- 
week variation of the PEFR increased after discontinuing steroids.
Conclusions.— Discontinuing inhaled steroids is possible in some patients with 
asthma or COPD after 2 years of regular treatment. This might indicate that for cer­
tain groups of patients with mild asthma or COPD, periodic treatment schedules with 
inhaled steroids is the treatment policy for the future.
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THE CURRENT understanding that 
inflammation is a major pathophysiologic 
mechanism underlying asthma1 and per- 
haps chronic obstructive pulmonary dis­
ease (COPD) as well2 has resulted in a 
shift in treatment policy to the early 
introduction of inhaled corticosteroids 
in the international guidelines.3'1 Sev­
eral studies5'10 have demonstrated that 
inhaled corticosteroids improve the long­
term corn’se of asthma and to a lesser 
degree of COPD.
Inhaled steroids have already been 
used for many years. Patient compli­
ance can be a problem, since inhaled 
steroids do not have a direct symptom- 
relieving effect and sometimes have side 
effects such as easy bruising, oral can­
didiasis, hoarseness or irritation of the 
oropharynx, osteoporosis, growth retar­
dation in children, or suppression of the 
adrenal gland. An important question 
for both physicians and patients is 
whether treatment with inhaled corti­
costeroids can be discontinued in a stable 
phase of the disease or if this therapy 
should be continued during the rest of 
the patient’s life. In other words, are we 
really treating the inflammatory pro­
cesses underlying the disease, or are we 
only suppressing these processes? Some 
studies have found that lung function 
deteriorates after reduction of inhaled 
steroids,11'10 but two long-term studies 
reported that after reducing or even 
stopping inhaled steroids, improvements 
in lung function could be maintained in 
some patients*17,18 So, although most 
studies suggest that asthma deteriorates 
after discontinuing steroids, results of
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Table 1.—Summary of Studies Concerning Stopping Inhaled Steroids Published to Date
Source
No. o! 
Patients Therapy, Duration Design
Measurements After 
Stopping Steroids
No. of 
Dropouts Results’"
Short-term Studies
Vathenen et al11 20 Budesonide 800 
ng, 6 wk
Open, between-patlent 
comparison
2-wk 2 FEV, and PD201 
Rescue medication T 
Symptoms t
Jenkins and 
Woolcock18
18 Beclomethasone 1200 
3 wk
Open, within-patient 
comparison
3-wk wash-out 
period
0 PD20 and PEFR I  
Diurnal variation t
Bel et al,a 8 Budesonide 800 
ng, 4 wk
Open, within-patlent 
comparison
4-wk wash-out 
period
0 FE V i stable 
PD20 i
Kraan et al'0 17 Budesonide 400 ¡.ig, 
4 wk
Open, withln-patient 
comparison
4-wk wash-out 
period
2 FEV, I  
PDgo ’!■
Long-term Studies •
Magnussen et all!i 15 Steroids, 2:6 mo Open, between-patient 
comparison
6 wk 5 FEVi i
p d 20 I
Waalkens et alU} 20 Budesonide 600 
i^g, i:28 mo
Double-blind, between- 
patient comparison
4 mo, after 2 mo of 
reduction
0 FEV, and PD20 i  
diPEFR stable 
Rescue medication T 
Symptoms T 
Exacerbations f
Juniper et alr/ 14 Budesonide 400
|tg. 1 y
Double-blind, between- 
patient comparison
3 mo: 8 slopped,
6 halved the dose
0 FEVi and PD^ stable 
Rescue medication stable 
Symptoms T
Haahtela ot al1,) 37 Budesonide 1200
|A0. 2 y
Double-blind, between- 
patient comparison
1 y: half stopped 
and hall tapered off to 
budesonide 400 |ig
5 FEV,, PEFR, and PDir, stable 
in tapering off group, but 
on average I  in group 
that stopped
Long-term remission in 6 
patients who stopped
!lFEV, indicates forced expiratory volume in 1 second; PC™, provocative concentration of histamine causing a 20% fall in FEV,; I, decreased; T, increased; PEFR, peak 
expiratory flow rate; diPEFR, diurnal peak expiratory flow rate; and PCir„ provocative concentration of histamine causing a 15% fall In FEV,.
recent long-term studies indicate that 
this might not be true for all patients. 
Table 1 represents a MEDLINE litera­
ture search of this subject over the past
12 years.
HYPOTHESIS
In controlled studies with inhaled ste­
roids, the lung* function improves and 
stabilizes within 3 to 0 months. The du­
ration of this new level of lung function 
seems to be stable for individual pa­
tients for a certain period of time. We 
believe that this period of time may be 
used to reduce or even stop the treat­
ment with inhaled steroids. This is prob­
ably dependent on the prognosis of the 
disease of individual patients, We hy­
pothesize that periodic treatment with 
inhaled corticosteroids is possible, at 
least in individual patients with mild 
asthma or CQPD (Figure).
EFFECTS OF DISCONTINUING 
INHALED STEROIDS
It is not clear how long patients should 
use inhaled steroids to treat the inflam­
matory processes underlying the dis­
ease. The duration of treatment with 
steroids in short-term studies111,1 did not 
exceed 0 weeks. It is likely that those 
studies neither treated the inflamma­
tory processes adequately nor were able 
to create a stable effect. However, alter 
stopping long-term use of inhaled cor­
ticosteroids, a progression of asthma was 
observed in two studies of patients with 
modem te-to-severe asthma. The study 
of Magnussen et alin confirmed that the
lung function deteriorated when steroids 
were stopped alter they had been used 
for 6 months. In a study with children 
who had received steroids for more than
2 years, forced expiratory volume in 1 
second (FEVi), symptom score, and 
change in bronchial hyperresponsive­
ness, indicated by a provocative con­
centration of histamine causing a 20% 
fall in FEVi (PCa(t) deteriorated.lti These 
findings were in contrast with the study 
of Juniper et aln of adults with mild 
asthma. They found that after reducing 
inhaled steroids (given regularly during
1 year), improvements in responsive­
ness and lung function could be main­
tained for at least 3 months. Recently, 
another study1* observed that the long­
term remission during a 2-year treat­
ment period with 1200 f i g  of budesonide 
was maintained well over 1 year in pa­
tients treated with a dose that was re­
duced three times and also in some pa­
tients receiving a placebo.
Comparable results were observed in 
our own study.151 We studied a group of 
48 patients with steroid-dependent 
asthma or COPD. All of these patients 
had shown a steep decline in FEVi of at 
least 80 mL per year and at least one 
exacerbation per year during 2 years of 
bronchodilator treatment.a(l They were 
treated additionally with 400 jig of be- 
clomethasone two times daily for an­
other 2 years.9 After 2 years of treat­
ment with inhaled steroids, patients 
were given the option to stop using ste­
roids. Sixteen patients were willing to 
stop using beclomethasone. They were
studied for another year in an open ob­
servational study. The subjects who 
dropped out did so because of personal 
reasons unrelated to their disease. Table
2 shows that no recruitment ,J)ias took 
place in this fifth year of follow-up: nei­
ther at the start nor at 2 to 4 years of the 
study were clinically (and statistically) 
significant differences observed between 
subjects who participated during the 
fifth year and subjects who did not. The 
only difference was that subjects who 
refused to continue this study after 4 
years were somewhat younger than sub- 
jects who finished this 5-year trial (48 vs 
56 years of age at the start of the study), 
which is not unexpected in the light of 
this very demanding* study. All subjects 
continued using broncho dilators in the 
same way as in the previous period (400 
f i g  of salbutamol or 40 |ig of ipratro­
pium bromide four times daily). Two of 
them developed carcinomas and dropped 
out of the study. The course of FEVi of 
the remaining 14 patients during the 
year in which beclomethasone was 
stopped was not significantly different 
when com])ared with the 2-year period 
of beclomethasone treatment (Table 8). 
Neither did the course of P(^„-hista­
mine, peak expiratory flow rate (PEFR), 
diurnal peak expiratory flow rate varia­
tion, symptom score, and exacerbation 
rate change. Only the week-to-week 
variation of the peak expiratory flow 
rate increased after discontinuing ste­
roids.
One of the aims of this observational 
study was to investigate whether there
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Table 3.— Mean Linear Change in or Mean Rate of Outcome Variables per Medication Period*
FEVi
A
-----Steroids Periodically
—  Bronchodilator Treatment Only
— - Steroids Continuously 
Steroid Treatment Period
Line 3
Line 1 Line 2
>T im e
Comparison of effect of periodic treatment and con­
tinuous treatment with inhaled steroids on lung func­
tion. Line 1 is based on observations in van Schayck 
et al;20 line 2 is based on Dompeling et al,9 and line 
3 represents our hypothesis. FEVt indicates forced 
expiratory volume in 1 second.
Table 2.— Patient Characteristics at the Start of the 
5-Year Study, at the Start of Beclomethasone 
(BDP) Treatment (After 2 Years), and at the Start of 
the Discontinuation of BDP (After 4 Years)’"
Characteristics!
Dropped
Out Continued
Start of Study
No. 32 16
Age, y 48 (1,9)$ 56 (2.3)
Sex
M 14 9
F 18 7
Smoker
Yes 15 9
No 17 7
Allergy
Yes 11 4
No 21 12
FEV„ L 2.11 (0.62) 2.02 (0.18)
FEV,, % of predicted 69 (3) 66 (4)
PC20§ 1.6 2.8
Reversibility, % of initial 17(2) 20 (5)
Symptom scoreJI 5.3 (0.3) 4.9 (0.4)
Start of Steroid Treatment (Third Year)
FEV,, % of predicted 59 (3) 56 (4)
Start of Discontinuation of Steroid Treatment
(Fifth Year)
FEVi, % of predicted 62 (4) 62 (3)
’"Comparisons were made between the group that 
dropped out of the study after 4 years and the group that 
continued the study but stopped BDP therapy at the 
start of the fifth year. Differences between the groups 
were tested by means of the unpaired Student’s f test 
and Wilcoxon t test for normally distributed variables, 
and xa test for dichotomic variables. Standard error of 
the mean shown in parentheses.
|FEV, indicates forced expiratory volume in 1 sec­
ond, and PC20, provocative concentration of histamine 
causing a 20% fall in FEV,.
tP<.05.
§PC20r expressed as milligrams of histamine per mil­
liliter, is given in geometric means.
¡(Symptom score is based on the adapted Dutch Medi­
cal Research Council questionnaire (in van Schayck20), 
ranging from 0 (no symptoms) to 8 (severe symptoms).
Yearly Change in 
Outcome Variable!
Steroid Treatment
P
I
0-2 y Before 2-4 y During
“ 1
4-5 y After
AFEV,, mL -104 (43) -9  (35) 43 (44) .47
APC20, doubling dose 0.5 (0.9) 0.3 (0.7) 0.2 (1.1) .94
APEFR, L/min -07(2 .4) 0.7 (2.0) -7 .5  (3.5) .11
AdiPEFR, % -0.2 (0.2) -0.3 (0.1) 0.4 (0.6) .34
AcovPEFR, % -0.7 (0.2) -0.6 (0.3) 0,3 (0.2) .02
ASymptom score, No, -0.06 (0.02) -0.004 (0.03) 0.08 (0.07) .40
Exacerbation rate, No. 1.3 (0.2) 0.9 (0.3) 0.7 (0.3) .55
'"Fourteen patients were treated with a bronchodilator alone during years 0 to 2, treated additionally with beclo­
methasone 800 |xg daily during years 2 to 4, and stopped the inhaled steroid during years 4 to 6. Differences between 
years 2 to 4 and years 4 to 5 were tested by the paired Student's f test. Standard error of the mean shown in 
parentheses.
tAindicates linear change in variable; FEV,, forced expiratory volume in 1 second; PC2o. provocative concentration 
of histamine causing a 20% fall in FEV,; PEFR, peak expiratory flow rate; diPEFR, diurnal peak expiratory flow rate; 
and covPEFR, week-to-week variation of peak expiratory flow rate.
is a subgroup of patients who do not have 
an increased decline in lung function af­
ter discontinuing steroids. Seven patients 
were shown to have a comparable de­
cline of FEVj and seven had an increased 
decline of FEVi after discontinuing be­
clomethasone in comparison with the pe­
riod of beclomethasone treatment. The 
patients with an increased decline after 
discontinuing steroids were more hyper- 
responsive at the start of the study than 
the patients with a comparable decline 
after discontinuing beclomethasone (PCa>,
0.37 vs 11.9 mg/mL, P=.005). Moreover, 
this subgroup tended to have a lower 
mean FEVi percentage predicted (56% 
vs 71%, P-.063) and a higher reversibil­
ity of obstruction (16.2% vs 7.1%, P=.08). 
No other variables (such as smoking be­
havior, allergy, and the like) could pre­
dict an increased decline of FEV! after 
stopping beclomethasone.
PERIODIC INDIVIDUAL INHALED 
CORTICOSTEROID REGIMEN
Reducing the dose of an inhaled ste­
roid or even stopping the use of inhaled 
steroids might be possible in individual 
patients in a stable phase of the disease. 
If the dose of steroids.is reduced or even 
discontinued, regular follow-up of pa­
tients is necessary to detect a new de­
terioration in lung function. To detect 
such a deterioration, regular lung func­
tion assessments by either the physi­
cian or the patient are required. When 
a new deterioration in lung function oc­
curs, the treatment regimen with ste­
roids can be raised or restarted for a 
certain period until a new stable phase 
has been attained. In this way, lung func­
tion can be optimized with the lowest 
dose of steroids, patient compliance may 
be increased, and the number and du­
ration of side effects can be reduced. 
Guidelines for general practitioners, pa­
tient education, and self-management 
plans with PEFR measurements are es­
sential for this purpose. There are stud-
ies that give reason to believe that pa­
tient education can improve the use of 
self-management skills.21 Patients can 
be trained in measuring their actual 
PEFR, which has shown to be a reliable 
indicator of the airway obstruction pre­
sent.22 Chai'lton et al stressed that it is 
of utmost importance to teach patients 
to interpret their symptoms and to in­
struct them how to take appropriate ac­
tion.2'’ Recently, the clinical efficacy of 
such a self-management plan has been 
proven24 and it has shown to reduce hos­
pital admissions,25 although it seems to 
be more effective in patients with more 
severe asthma.20
One of the questions that has not been 
answered so far is whether it is enough to 
rely on the assessment of the PEFR mea­
surement (with or without symptoms) in 
self-management plans. There are recent 
indications that during steroid treatment, 
lung function (FEVi, PEFR) recovers 
faster than bronchial hyperresponsive­
ness (PC20).5’27 This might indicate that 
the underlying inflammation (indicated 
by the bronchial hyperresponsiveness) 
has not yet recovered, while the lung func­
tion is already within the normal range. 
It is not clear whether this indicates that 
longer steroid treatment is necessary than 
could be expected on the basis of PEFR 
measurement and/or symptoms. Further 
long-term placebo-controlled double-blind 
studies will have to be performed to as- 
( sess the optimal duration of treatment 
with inhaled steroids. It is our hypothesis 
that in the long run, the prognosis is not 
worse (or even better) during periodic 
treatment than during continuous treat­
ment with inhaled steroids. This is illus­
trated by line 3 in the Figure. (This Fig­
ure is partly based on observations [line
1, “bronchodilator treatment only/’ is 
based on van Schayck et aP; line 2, 44con­
tinuous inhaled steroid treatment/’ is 
based on Dompeling et al9] and partly 
based on hypothetical considerations [line 
3, “periodic inhaled steroid treatment”]).
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If discontinuing inhaled steroids is pos­
sible after some time of regular treat­
ment, periodic treatment schedules with 
inhaled steroids might be the treatment 
policy for the future for certain groups
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